Faron promotes Juho Jalkanen to COO post

Shares of Finnish clinical-stage biopharma Faron Pharmaceuticals (AIM: FARN) were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. Dr Jalkanen will continue to be based in Turku, Finland and his appointment is effective immediately. 

In his new role, Dr Jalkanen will lead business strategy and daily operations for Faron. This includes oversight of academic and industry partnerships, resource prioritization and allocation, chemistry, manufacturing and controls, supply chain and driving performance measures.

His priority will be the accelerated development of bexmarilimab, Faron’s wholly-owned, novel precision cancer immunotherapy candidate. Bexmarilimab is currently in development as a potential monotherapy in patients with solid tumors. Faron is also advancing plans to study bexmarilimab in the neoadjuvant setting, in combination with checkpoint inhibitors and as a treatment for hematological malignancies.

"Dr Jalkanen is an experienced biopharmaceutical industry executive with extensive leadership experience across key functional areas including operations, business development, clinical development, medical and regulatory affairs," said Dr Markku Jalkanen, chief executive of Faron.

Also recruiting for CBO